Intelligent Bio's Q2 Loss Widens As FDA Application Planned For Year-End; Stock Down

Intelligent Bio Solutions (INBS) submitted a 510(k) application to the FDA for its drug screening system, which uses fingerprint sweat analysis. The company reported clinical data showing over 98% accuracy and 100% specificity in detecting codeine. FDA clearance could expand U.S. market opportunities. INBS stock closed at $2.15, up 4.02% in pre-market trading.

INTELLIGENT BIO SOLUTIONS INC. (INBS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth Reader installed base grew 22% year-over-year, driving a 35% increase in total consumable cartridges to over

Biotech gainers were led by 4D Molecular Therapeutics (FDMT), up over 12%, after Phase 3 enrollment progress for 4D-150 in wet AMD and other pipeline updates, plus a $200M credit facility. OmniAb (OABI) rose over 11% on an Eli Lilly collaboration and higher 2026 cash guidance. Acurx (ACXP) gained over 14% after FDA conditional acceptance of CIFBEZY as ibezapolstat’s brand name.

Costco (COST) reported Q4 FY26 results with net sales up 11.2% YoY to $93.87B and net income up 14.9% to $3.00B. Memberships grew 3.8% YoY to 84.1M, with executive memberships up 9.4%. Digital sales rose 19.5%. The company's strong cash flow and low debt position it well for future investments.

TotalEnergies aims to boost oil, gas, and electricity production by 4% annually through 2030, adding $10 billion in free cash flow by 2030. The company expects oil and gas production to rise over 3% annually, while electricity generation grows over 20% annually, reaching 100-120 TWh by 2030. TotalEnergies plans to invest $14-17 billion annually from 2027-2032 and increase dividends by over 5% annually from 2026-2030.

TotalEnergies (TTE) stock rose 2% premarket after reaffirming long-term growth targets, including 3%+ annual oil/gas production growth and 4% overall energy production growth through 2030. The company aims for 50% reduction in Scope 1/2 emissions and 80% methane reduction by 2030. It plans $14B-$17B annual investments from 2027-2032, 5%+ dividend growth, and $2.5B-$2.5B share buybacks in 2026-2027. Analysts have mixed views; TTE trades at $92.40, with a Buy consensus and $97.67 avg.